

Oncology Test Request

Client Information (required) Client Name Client Account No. Client Phone Client Order No. Address City State Zip Code Submitting Provider/Provider Name Information (required)

Submitting Provider/Provider Name Information (required)	
Submitting/Referring Provider (Last, First)	

Submitting/Referring Provider (Last, First)
Fill in only if Call Back is required. Phone ()
Fax* ()
Provider's National I.D. (NPI)

Pathologist's Name (required)

Submitting/Referring Pathologist (Last, First)		
Phone ()	
Fax* ()	
Fax* ()	

New York State Patients: Informed Consent for Genetic Testing

"I hereby confirm that informed consent has been signed by an individual legally	
authorized to do so and is on file with this office or the individual's provider's office."	
Signature	
Signature	

Note: It is the client's responsibility to maintain documentation of the order.

MCI Internal Has Only
MCL Internal Use Only

Ship specimens to:

Mayo Clinic Laboratories 3050 Superior Drive NW Rochester, MN 55901

Customer Service: 855-516-8404

 $\label{thm:composition} \textit{Visit www.} \textit{MayoClinicLabs.com} \ \textit{for the most up-to-date test and shipping information}.$

Patient Information (required)

Patient ID (Medical Record No.)		
Patient Name (Last, First, Middle)		
Gender □ Male □ Female	Birth Date (Mo	nth DD, YYYY)
Collection Date (Month DD, YYYY)		⊒ a.m. ⊒ p.m.

Specimens Provided (required)

☐ Blood	☐ Paraffin block	□ Tissue		
☐ Bone Marrow	No. sent:	No. sent:		
☐ Fixed Cells	Indicate source:	☐ Frozen		
☐ Cultured Cells		☐ Fixed Formalin		
□ DNA		☐ Wet Tissue		
☐ Lymph Node	☐ Slides	☐ Other Fixative		
☐ Spleen	No. sent:	type:		
		☐ Other		
		Anatomic site:		
CBC results:				
HB	RBC	WBC		
HCT	MCV	PLT		
If ordering HER2	If ordering HER2 testing:			

Was specimen fixed in 10% neutral buffered formalin within 1 hour from surgical collection time?

☐ Yes ☐ No

Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours?

]	Yes	No

Pathology/Clinical Diagnosis (required)

(Include a brief history, pertinent laboratory results, suspected diagnosis, and reason for referral.)
ICD-10 Diagnosis Code

Rilling Information

- · An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing related questions: 800-447-6424 (US and Canada) 507-266-5490 (outside the US)

^{*}Fax number given must be from a fax machine that complies with applicable HIPAA regulation.

Tax number given must be nom a fax machine that complies with applicable thr AA regulation.

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
,	
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (Month DD, YYYY)	

FEATURED ONCOLOGY TESTING

PD-L1 Immunohistochemical stains				
□ SP263	Programmed Death-Ligand 1 (PD- L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual			
□ SP142	Programmed Death-Ligand 1 (PD- L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual			
□ 22C3	Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual			
Microsatellite Instability (MSI)/Mismatch Repair				
Microsatel	lite Instability (MSI)/Mismatch Repair			
Microsatel TMSI	lite Instability (MSI)/Mismatch Repair Microsatellite Instability, Tumor			
	, , ,			
☐ TMSI	Microsatellite Instability, Tumor Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor			
☐ TMSI☐ IHC	Microsatellite Instability, Tumor Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor			
☐ TMSI☐ IHC	Microsatellite Instability, Tumor Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor on Testing			

Pathology Consultation

PATHOLOGY

☐ PATHC

Next-Generation Sequencing (NGS) Panels				
□ GISTP	Gastrointestinal Stromal Tumor (GIST) Targeted Gene Panel, Next-Generation Sequencing, Tumor			
□ LNGPR	Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor			
☐ MELP	Melanoma Targeted Gene Panel, Next- Generation Sequencing, Tumor			
□ NONCP	Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor			
□ RASFP	RAS/RAF Targeted Gene Panel, Next- Generation Sequencing, Tumor			
□ SARCP	Sarcoma Targeted Gene Fusion/ Rearrangement Panel, Next-Generation Sequencing, Tumor			
□ CAPN	Solid Tumor-Targeted Cancer Gene Panel, Next-Generation Sequencing			

Myxoid/Round Cell Liposarcoma, 12q13 (DDIT3 or CHOP) Rearrangement, FISH,

☐ DDITF

Chromosomal Microarray			
☐ CMAPT	Chromosomal Microarray, Tumor, Formalin- Fixed Paraffin-Embedded		
Cell-Free D	DNA (cfDNA) Testing		
□ BRAFB	Cell-Free DNA BRAF V600 Test, Blood		
□ EGFRD	EGFR Exon 18, 19, 20, 21, Mutation Analysis, Cell-Free DNA, Plasma		
□ T790M	Cell-Free DNA EGFR T790M Mutation Analysis, Blood		
☐ KRASD	Cell-Free DNA KRAS 12, 13, 61, 146, Blood		

ПАПІО	Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis
PATHOLOG	Y: TARGETED TUMOR TESTING
Bone and S	Soft Tissue
□ F0X0F	Alveolar Rhabdomyosarcoma (ARMS), 13q14 (F0X01 or FKHR) Rearrangement, FISH, Tissue
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue
□ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue
□ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue
☐ CTNNB	Beta-Catenin (CTNNB1) Mutation Analysis, Tumor
□ ESTUF	Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue
□ EWSF	Ewing Sarcoma (EWS), 22q12 (EWSR1) Rearrangement, FISH, Tissue
□ IMTF	Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH, Tissue
□ MDM2F	MDM2 (12q15) Amplification, Well- Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue

	Tissue
□ MYCNF	Neuroblastoma, 2p24 (MYCN) Amplification, FISH, Tissue
□ PDGF	PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue
□ SS18F	Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue
□ USPF	USP6 (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue
Breast	
□ MASF	Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue
☐ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue
☐ H2BR	HER2 Amplification Associated with Breast Cancer, FISH, Tissue
□ ESR1	Estrogen Receptor 1 (ESR1) Mutation Analysis, Tumor
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue
	tochemical assays interpreted image analysis
□ ERPR	Estrogen/Progesterone Receptor, Semi- Quantitative Immunohistochemistry, Manual
☐ KI67B	Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
□ HERBA	HER2, Breast, Quantitative

☐ HERBN	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex		
□ HERDM	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex		
☐ HERDN	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex		
Gastrointe	stinal		
□ BILA0	Biliary Tract Malignancy, FISH		
□ BRAFT	BRAF Mutation Analysis (V600E), Tumor		
□ EGFRT	EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor		
□ PRKAF	Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue		
☐ FGFR2	FGFR2 (10q26.1) Rearrangement, FISH, Tissue		
☐ GISTP	Gastrointestinal Stromal Tumor (GIST) Targeted Gene Panel, Next-Generation Sequencing, Tumor		
□ H2GE	HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue		
☐ H2MT	HER2 Amplification, Miscellaneous Tumor, FISH, Tissue		
□ HERGM	HER2, Gastric/Esophageal, Semi- Quantitative Immunohistochemistry, Manual		
□ HERGN	HER2, Gastric/Esophageal, Semi- Quantitative Immunohistochemistry, Manual, No Reflex		

HER2 FISH Reflex

Immunohistochemistry, Automated with

Patient Information (required)

Patient ID (Medical Record No.)				Client Account No.			
Patient Name (Last, First, Middle)			Client Order No.				
Birth Date (Month DD, YYYY)							
☐ KINET	☐ KINET Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated ☐ FGF1F		and Neck F1F FGFR1 (8p11.2) Amplification, FISH, Tissue		□ LUNGP	Lung Cancer-Targeted Gene Panel, Tumor Lung Cancer Rearrangement Testing, Tumor	
□ KRASC	KRAS Mutation Analysis, 7 Mutation Panel, Colorectal	☐ HPVHL Human Papillomavi Risk, DNA In Situ H		omavirus (HPV) High/Low Situ Hybridization	RETF	Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue	
□ METF	MET (7q31), FISH, Tissue	☐ HPVHR Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization		□ ROS1F	Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue		
☐ ML1HM ☐ BRMLH	MLH1 Hypermethylation Analysis, Tumor MLH1 Hypermethylation and BRAF	☐ HPVLR Human Papillomavirus (HPV), Low-Risk,		☐ METF	MET (7q31), FISH, Tissue		
	Mutation Analysis, Tumor	DNA In Situ Hybridization MAMLF MAML2 (11q21) Rearrangement,		ONCOLOGY	: MOLECULAR DIAGNOSTIC TESTING		
□ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor	Mucoepidermoid Carcinoma (MEC), FISH, Tissue		oid Carcinoma (MEC), FISH,	Gastrointe		
☐ TMSI	Microsatellite Instability, Tumor	□ SGTF	MYB (6q23) R	earrangement, FISH, Tissue	☐ APCZ ☐ LYNCH	APC Gene, Full Gene Analysis Lynch Syndrome Panel	
□ RASFP	RAS/RAF Targeted Gene Panel, Next-	Melanoma			☐ MLH1Z	MLH1 Gene, Full Gene Analysis	
	Generation Sequencing, Tumor	□ BRAFB	Cell-Free DNA	A BRAF V600, Blood	☐ MSH2Z	MSH2 Gene, Full Gene Analysis	
Genitourina		□ BRAFC	BRAF Mutatio	n Analysis (V600), Melanoma	□ MSH6Z	MSH6 Gene, Full Gene Analysis	
☐ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3),	☐ MELF	Melanoma, Fl	·	□ MYHZ	MUTYH Analysis, Full Gene Analysis	
	FISH, Tissue	☐ MELP		rgeted Gene Panel, Next-	□ PMS2Z	PMS2 Gene, Full Gene Analysis	
□ GCTF	Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue	□ ИММЗЕ		equencing, Tumor ma, Chromosome 3 Monosomy,	□ U1A1V	UDP-Glucuronosyl Transferase 1A1 TA Repeat Genotype, UGT1A1	
☐ H2UR	HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue	Neuro-onc			□ UGTFG	UDP-Glucuronosyl Transferase 1A1 (UGT1A1), Full Gene Sequencing	
□ FUROC	UroVysion for Detection of Bladder Cancer,	☐ GLIOF 1p/19q Deletion in Gliomas, FISH, Tissue		Inherited Endocrine			
	Urine	□ BRAFT	BRAF Mutatio	n Analysis (V600E), Tumor	□ RETZ	RET Proto-Oncogene, Full Gene Analysis	
□ NUT1F	NUTM1 (15q14) Rearrangement, FISH, Tissue	☐ CMAPT	Chromosomal Fixed Paraffin	Microarray, Tumor, Formalin- -Embedded	□ SDHP □ VHLZ	SDHB, SDHC, SDHD Gene Panel VHL Gene, Full Gene Analysis	
□ PR0F	Prostate Tumor, FISH, Tissue	□ GCTF		nor (GCT), Isochromosome 12p,			
☐ TFEBF	Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue	□ IDH12		ate Dehydrogenase 1 and 2	PRIMARY BODY FLUID TESTS Tests for disease monitoring or aiding in the diagnosis		
Gynecology		☐ MEDF	(IDH1/IDH2) Mutation Analysis, Tumor MEDF Medulloblastoma, FISH, Tissue MEDF Medulloblastoma, FISH, Tissue		Soft Tissue		
Endometrial	/Uterine Carcinoma	□ MGMT		ter Methylation, Tumor	☐ IFG23	Intact Fibroblast Growth Factor 23, Serum	
□ ESTUF	Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE)	□ NONCP		gy Expanded Panel with	Breast ☐ C2729	Breast Carcinoma-Associated Antigen,	
☐ ML1HM	Rearrangement, FISH, Tissue MLH1 Hypermethylation Analysis, Tumor	□ TERT	•	er Analysis, Tumor		Serum	
Ovarian Carcinoma		Pulmonary			☐ CA153	Cancer Antigen 15-3 (CA 15-3), Serum	
□ XL2	FOXL2 Mutation Analysis, Tumor	□ BRAFT	BRAF Mutatio	n Analysis (V600E), Tumor	Endocrine		
Gestational/Trophoblatic Disease/ Molar Pregnancy		□ EGFRT		Iutation Analysis, 29 Mutation	Thyroid Can	icer	
□ POCF	Products of Conception (POC) Aneuploidy	□ FGF1F	Panel, Tumor FGFR1 (8p11.	2) Amplification, FISH, Tissue	☐ CATLN	Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node	
Detection, FISH, Paraffin-Embedded Tissue		☐ KRASO	KRAS Mutatio	on Analysis, 7 Mutation Panel,	□ CATN	Calcitonin, Serum	
Lower Anal-Genital Tract Carcinoma			Other (Non-Co	, , , , , , , , , , , , , , , , , , ,	□ CEA	Carcinoembryonic Antigen (CEA), Serum	
☐ HPVE6	Human Papillomavirus (HPV) High-Risk E6/ E7, RNA In Situ Hybridization	□ LCAF	FISH, Tissue	ALK (2p23) Rearrangement,	☐ TGMS ☐ TFNAB	Thyroglobulin Mass Spectrometry, Serum Thyroglobulin, Tumor Marker, Fine-Needle	
☐ HPVHL	Human Papillomavirus (HPV) High/Low	□ EGFRR		EGFR with ALK Reflex, Tumor		Aspiration Biopsy Needle Wash	
Risk, DNA In Situ Hybridization HPVHR Human Papillomavirus (HPV), High-Risk,		□ LNGPR	Lung Cancer- Rearrangeme	Targeted Gene Panel with nt, Tumor	☐ HTGR ☐ HTG2	Thyroglobulin, Tumor Marker Reflex, Serum Thyroglobulin, Tumor Marker, Serum	
	DNA In Situ Hybridization				□ піц2	THYTOGIODUIIII, TUIIIOI WAIKEI, SETUIII	
☐ HPVLR	Human Papillomavirus (HPV), Low-Risk, DNA In Situ Hybridization						

Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (Month DD, YYYY)	

Birth Date (Month DD, YYYY)				
Neuroendo	crine Tumors			
☐ CGAK	Chromogranin A, Serum			
☐ GAST	Gastrin, Serum			
☐ GLP	Glucagon, Plasma			
□ NSE	Neuron-Specific Enolase (NSE), Serum			
☐ HPP	Pancreatic Polypeptide, Plasma			
□ VIP	Vasoactive Intestinal Polypeptide, Plasma			
Pituitary Tu	imors			
☐ ACTH	Adrenocorticotropic Hormone, Plasma			
☐ APGH	Alpha-Subunit Pituitary Tumor Marker, Serum			
□ FSH	Follicle-Stimulating Hormone (FSH), Serum			
☐ HGH	Growth Hormone, Serum			
□ LH	Luteinizing Hormone (LH), Serum			
☐ MCRPL	Macroprolactin, Serum			
□ NSE	Neuron-Specific Enolase (NSE), Serum			
□ PLPMA	Prolactin, Pituitary Macroadenoma, Serum			
□ PRL	Prolactin, Serum			
Biogenic Aı	mines			
□ CATU	Catecholamine Fractionation, Free, 24 Hour,			
L OATO	Urine Urine			
\square CATP	Catecholamine Fractionation, Free, Plasma			
□ HVA	Homovanillic Acid, 24 Hour, Urine			
☐ HVAR	Homovanillic Acid, Random, Urine			
☐ HIAA	5-Hydroxyindoleacetic Acid, 24 Hour, Urine			
☐ METAF	Metanephrines, Fractionated, 24 Hour, Urine			
☐ PMET	Metanephrines, Fractionated, Free, Plasma			
☐ METAR	Metanephrines, Fractionated, Random, Urine			
☐ SERU	Serotonin, 24 Hour, Urine			
□ SERWB	Serotonin, Blood			
□ VH	VanillyImandelic Acid and Homovanillic Acid, Random, Urine			
□ VMA	VanillyImandelic Acid, 24 Hour, Urine			
□ VMAR	VanillyImandelic Acid, Random, Urine			
Gastrointe	estinal			
□ L3AFP	Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum			
☐ AFPPT	Alpha-Fetoprotein (AFP), Peritoneal Fluid			
☐ AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum			
□ AMLPC	Amylase, Pancreatic Cyst Fluid			
□ 199PC	Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid			
□ 199PT	Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid			
☐ CA19	Carbohydrate Antigen 19-9 (CA 19-9), Serum			

☐ CEAPC	Carcinoembryonic Antigen (CEA), Pancreatic				
□ CEAPT	Cyst Fluid Carcinoembryonic Antigen (CEA), Peritoneal				
	Fluid				
□ CEA	Carcinoembryonic Antigen (CEA), Serum				
□ CGAK □ DCP	Chromogranin A, Serum Des-Gamma-Carboxy Prothrombin, Serum				
	•				
□ FOBT	Fecal Occult Blood, Colorectal Cancer Screen, Qualitative, Immunochemical, Feces				
☐ GAST	Gastrin, Serum				
☐ GLP	Glucagon, Plasma				
☐ HCCGS	Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum				
☐ HIAA	5-Hydroxyindoleacetic Acid, 24 Hour, Urine				
□ NSE	Neuron-Specific Enolase (NSE), Serum				
□ НРР	Pancreatic Polypeptide, Plasma				
□ SERU	Serotonin, 24 Hour, Urine				
☐ SERWB	Serotonin, Blood				
□ VIP	Vasoactive Intestinal Polypeptide, Plasma				
Genitourin	ary				
☐ AFPSF	Alpha-Fetoprotein (AFP), Spinal Fluid				
□ AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum				
□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum				
□ BHSF	Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid				
□ CEASF	Carcinoembryonic Antigen (CEA), Spinal Fluid				
□ PSA	Prostate-Specific Antigen (PSA) Diagnostic, Serum				
□ SPSA	Prostate-Specific Antigen (PSA) Screen, Serum				
☐ PHI11	Prostate Health Index (phi), Serum				
□ PSAFT	Prostate-Specific Antigen (PSA), Total and Free, Serum				
Gynecolog	Gynecology				
□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum				
□ CA25	Cancer Antigen 125 (CA 125), Serum				
☐ HE4	Human Epididymis Protein 4, Serum				
□ INHA	Inhibin A, Tumor Marker, Serum				
□ INHAB	Inhibin A and B, Tumor Marker, Serum				
□ INHB	Inhibin B, Serum				
1					

Pulmonary	
□ PF199	Carbohydrate Antigen 19-9 (CA 19-9), Pleura Fluid
□ PFCEA	Carcinoembryonic Antigen (CEA), Pleural Fluid
□ NSE	Neuron-Specific Enolase (NSE), Serum
ADDITIONA (INDICATE)	L TESTS TEST CODE AND NAME)

ROMA Score (Ovarian Malignancy Risk

Algorithm), Serum

□ ROMA